Alteplase is currently the only approved thrombolytic agent for treatment of acute ischaemic
stroke, but interest is burgeoning in the development of new thrombolytic agents for systemic …

Cardiovascular diseases, such as myocardial infarction, ischemic stroke, and pulmonary
embolism, are the most common causes of disability and death worldwide. Blood clot …

Background Antagonists of glycoprotein VI-triggered platelet activation used in combination
with recanalisation therapies are a promising therapeutic approach in acute ischaemic …

Alteplase is the only FDA-approved drug for thrombolysis in acute ischemic stroke (AIS).
Meanwhile, several thrombolytic drugs are deemed to be promising candidates to substitute …

Background There has been debate on the use of intravenous thrombolysis (IVT) in patients
with ischemic stroke and the recent use of direct oral anticoagulants (DOACs). Studies have …

There is no blood biomarker diagnostic of arterial thrombosis. We investigated if arterial
thrombosis per se was associated with alterations in complete blood count (CBC) and white …

The plasminogen activator staphylokinase is a fibrin-specific thrombolytic biomolecule and
an attractive target for the development of effective myocardial infarction and stroke therapy …

Stroke burden is substantially increasing but current therapeutic drugs are still far from ideal.
Here we highlight the vast potential of staphylokinase as an efficient, fibrin-selective …

Ethnopharmacological relevance Many studies have demonstrated the powerful
neuroprotection abilities of multiple traditional Chinese medicines (TCMs) against NLRP3 …

Intravenous thrombolysis with a recombinant tissue plasminogen activator (rt-PA) is the first-
line treatment of acute ischemic stroke. However, successful recanalization is relatively low …